Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB known ✓ | P27338 | 4/20 | 0.52 |
| ▸ | MAOA known ✓ | P21397 | 3/20 | 0.52 |
| ▸ | HTR2C known ✓ | P28335 | 1/20 | 0.50 |
| ▸ | DRD4 known ✓ | P21917 | 2/20 | 0.43 |
| ▸ | DRD2 known ✓ | P14416 | 1/20 | 0.42 |
| ▸ | DRD1 known ✓ | P21728 | 1/20 | 0.42 |
| ▸ | DRD3 known ✓ | P35462 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.80 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | PNMT | P11086 | 1/20 | 0.43 |
| ▸ | CD44 | P16070 | 1/20 | 0.43 |
| ▸ | DRD5 | P21918 | 1/20 | 0.42 |
| ▸ | IDO1 | P14902 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.40 |
| ▸ | BAD | Q92934 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL28824329 | 1.00 | TSHR (0.80) | TSHRMAOBMAOACYP2A6HTR2C | |
| Hydrochloric Acid SCHEMBL30332134 | 1.00 | TSHR (0.80) | TSHRMAOBMAOACYP2A6HTR2C | |
| SCHEMBL9662 | 0.96 | — | — | |
| SCHEMBL3057782 | 0.96 | TSHR (0.86) | TSHRMAOBMAOACYP2A6HTR2C | |
| SCHEMBL451157 | 0.96 | TSHR (0.86) | TSHRMAOBMAOACYP2A6HTR2C | |
| SCHEMBL29354295 | 0.96 | — | — | |
| SCHEMBL8676208 | 0.93 | TSHR (0.80) | TSHRMAOBMAOACYP2A6HTR2C | |
| Hydrochloric Acid SCHEMBL5800421 | 0.93 | TSHR (0.93) | TSHRMAOBMAOACYP2A6HTR2C | |
| Ammonia Solution, Strong SCHEMBL6332955 | 0.93 | TSHR (0.80) | TSHRMAOBMAOACYP2A6HTR2C | |
| Ammonia Solution, Strong SCHEMBL1151087 | 0.93 | TSHR (0.80) | TSHRMAOBMAOACYP2A6HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11597727-B2 | Inhibitors of integrin alpha 2 beta 1 and methods of use | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-03-07 | — | — | US | disclosed |
| EP-3555082-B1 | ETHER LINKED TRIAZOLES AS NRF2 REGULATORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2022-01-26 | — | — | EP | disclosed |
| US-20220002272-A1 | BISARYL LACTAMS AS NRF2 ACTIVATORS | ASTEX THERAPEUTICS LIMITED (GB) | 2022-01-06 | — | — | US | disclosed |
| US-20210387986-A1 | INHIBITORS OF INTEGRIN ALPHA 2 BETA 1 AND METHODS OF USE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2021-12-16 | — | — | US | disclosed |
| US-11059816-B2 | Ether linked triazoles as NRF2 activators | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-07-13 | — | — | US | disclosed |
| EP-3796906-A1 | INDANES AS NRF2 ACTIVATORS | GlaxoSmithKline Intellectual Property Management Limited (GB) | 2021-03-31 | — | — | EP | disclosed |
| EP-3765005-A1 | INHIBITORS OF INTEGRIN ALPHA 2 BETA 1 AND METHODS OF USE | The Regents of the University of California (US) | 2021-01-20 | — | — | EP | disclosed |
| EP-3555068-B1 | 3-OXO-1,4-DIAZEPINYLE COMPOUNDS AS NRF2 ACTIVATORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2020-12-02 | — | — | EP | disclosed |
| US-20200071317-A1 | ETHER LINKED TRIAZOLES AS NRF2 ACTIVATORS | ASTEX THERAPEUTICS LIMITED (GB) | 2020-03-05 | — | — | US | disclosed |
| EP-3555068-A1 | 3-OXO-1,4-DIAZEPINYLE COMPOUNDS AS NRF2 ACTIVATORS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2019-10-23 | — | — | EP | disclosed |
| EP-3555082-A1 | ETHER LINKED TRIAZOLES AS NRF2 REGULATORS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2019-10-23 | — | — | EP | disclosed |
| WO-2019178248-A1 | INHIBITORS OF INTEGRIN ALPHA 2 BETA 1 AND METHODS OF USE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-09-19 | — | — | WO | disclosed |
| CN-106946707-B | Polysubstituted hydrogenation indene derivative of one kind and preparation method thereof | 安徽师范大学 | 2018-08-31 | — | — | CN | disclosed |
| WO-2018109649-A1 | ETHER LINKED TRIAZOLES AS NRF2 REGULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-06-21 | — | — | WO | disclosed |
| WO-2018109648-A1 | 3-OXO-1,4-DIAZEPINYLE COMPOUNDS AS NRF2 ACTIVATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-06-21 | — | — | WO | disclosed |
| CN-106946707-A | A kind of polysubstituted hydrogenation indene derivative and preparation method thereof | 安徽师范大学 | 2017-07-14 | — | — | CN | disclosed |
| CN-1107844-A | Indane derivative, processes for preparing the same and synthetic intermediate of the same | TANABE SEIYAKU CO (JP) | 1995-09-06 | — | — | CN | disclosed |
| CN-1016506-B | Preparation method of 1, 2-indane sulfonamide compound with antiarrhythmic drug activity | PFIZER LTD (GB) | 1992-05-06 | — | — | CN | disclosed |
| EP-0014951-A2 | Heterocyclic oxypropanolamine derivatives, process for their preparation and medicines containing these compounds | Roche Diagnostics GmbH (DE) | 1980-09-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11059816-B2 | Ether linked triazoles as NRF2 activators | NFE2L2, KEAP1, NQO1 | MAOB 1748/4885MAOA 1387/4885HTR2C 1821/4885 |
| US-11597727-B2 | Inhibitors of integrin alpha 2 beta 1 and methods of use | ITGB1, ITGB2, ITGA2 | MAOB 2880/4885MAOA 3616/4885HTR2C 3918/4885 |
| US-20210387986-A1 | INHIBITORS OF INTEGRIN ALPHA 2 BETA 1 AND METHODS OF USE | ITGB1, ITGB2, ITGA2 | MAOB 2880/4885MAOA 3616/4885HTR2C 3918/4885 |
| US-20200071317-A1 | ETHER LINKED TRIAZOLES AS NRF2 ACTIVATORS | NFE2L2, KEAP1, NQO1 | MAOB 1748/4885MAOA 1387/4885HTR2C 1821/4885 |
| US-20220002272-A1 | BISARYL LACTAMS AS NRF2 ACTIVATORS | KEAP1, NFE2L2, NQO1 | MAOB 715/4885MAOA 584/4885HTR2C 3417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.